First Patient Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites
First Patient Enrolled in BioVie Phase 2a Clinical Trial of BIV201 for Ascites September 14, 2017 BEVERLY, MA–(Marketwired – September 14, 2017) – BioVie Inc. (OTCQB: BIVI), a clinical-stage company focused on the discovery, development, and commercialization of innovative drug therapies for liver disease, today confirmed enrollment of the first patient in the Company’s mid-stage (Phase 2a) clinical trial of BIV201 for the treatment of patients with refractory ascites due to liver cirrhosis. The initial trial is being led by Jasmohan Bajaj, MD, MS, study site principal investigator (PI) at the McGuire Research Institute in Richmond, VA.The study titled Safety and pharmacodynamic activity of low-dose terlipressin delivered by continuous intravenous infusion in patients with cirrhosis and refractory ascites requiring recurrent large volume paracentesis is an open-label prospective study in a cohort of 6 patients who are refractory to, or intolerant of, diuretic therapy. In addition to examining the [...]